AMBELVIST SOLUTION FOR INJECTION 0.1MMOL/ML [SIN17631P]
Active ingredients: GADOQUATRANE
Product Info
AMBELVIST SOLUTION FOR INJECTION 0.1MMOL/ML
[SIN17631P]
Product information
Active Ingredient and Strength | GADOQUATRANE - 0.1 MMOL/ML |
Dosage Form | INJECTION, SOLUTION |
Manufacturer and Country | BAYER AG - GERMANY |
Registration Number | SIN17631P |
Licence Holder | BAYER (SOUTH EAST ASIA) PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | V08CA13 |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
4.1 Indications
This medicinal product is for diagnostic use only.
Ambelvist is indicated in adults and paediatric patients of all ages including term neonates for contrast enhancement in magnetic resonance imaging (MRI) to detect and visualise known or suspected pathology in the central nervous system (the brain, spine, and associated tissues) and body (head and neck, thorax, abdomen, pelvis, extremities).
Dosing
4.2 Dosage and method of administration
4.2.1 Method of administration
This medicinal product is for intravenous administration only.
The intravenous administration should be followed by a flush of 0.9% sodium chloride solution.
After administration, the patient should be kept under observation for at least half an hour, since experience with other gadolinium-based contrast agents (GBCAs) shows that most undesirable effects occur within this time period (see section 4.4 Special warnings and precautions for use – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Instructions for use and handling
Visually inspect Ambelvist prior to administration. Do not use the solution if it is discoloured, if particulate matter is present or if the container appears damaged.
Do not mix Ambelvist with other medications because of the potential for chemical incompatibility.
Vials and bottles
For the vial and bottle presentations, do not pierce the rubber stopper more than once.
When used in a single use setting, Ambelvist is for use in a single patient only. Any contrast agent solution not used in one examination must be discarded.
Use of Ambelvist in a single-use setting
Vials or bottles containing contrast medium solutions are not intended for the withdrawal of multiple doses.
The rubber stopper of the vial or bottle should never be pierced more than once.
Each vial or bottle should be used in one patient on one occasion only and any residue should be discarded. Ambelvist contains no preservatives.
If a single-use injector system is used, Instructions For Use (IFU) of the device manufacturer must be followed, including connecting tubes and all disposable parts. Ensure the single-use disposables are replaced after each patient.
Use of Ambelvist with a multi-patient use injector system and/or large volume containers (30 mL vials or 65 mL bottles)
The transmission of viral infections and bacterial contamination are recognised but rare potential complications of multi-use containers and administration devices. The following measures should be strictly adhered to when using Ambelvist:
The multiple withdrawal and administration of contrast medium must be done utilising a device and disposables system validated and approved for multi-patient use, such as an automatic injector system.
The rubber stopper of the bottle should never be pierced more than once.
Instructions For Use (IFU) of the device manufacturer must be followed, including connecting tubes and all disposable parts of the injector system. Ensure the single-use disposables are replaced after each patient.
A maximum use time of 4 hours from initial puncture is permitted to complete fluid transfer. Discard any unused Ambelvist solution 4 hours after initial puncture.
In a microbial ingress challenge study performed with a multi-patient use kit, there was no contamination of Ambelvist over a 24-hour period. The in-use time should not be more than 24 hours and as per the approved IFU of the device manufacturer.
4.2.2 Dosage
The dose should be calculated based on the patient’s body weight and should not exceed the recommended dose per kilogram of body weight detailed in this section.
An intravenous injection of 0.1 mL per kg body weight (BW) of Ambelvist is recommended. This is equivalent to 0.01 mmol gadoquatrane per kg body weight or 0.04 mmol gadolinium (Gd) per kg body weight.

4.2.3 Special patient populations
4.2.3.1 Paediatric patients
No dose adjustment is required (see section 5.2 Pharmacokinetic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Neonates up to 4 weeks of age and infants up to 1 year of age
Due to immature renal function in neonates up to 4 weeks of age and infants up to 1 year of age, Ambelvist should only be used in these patients after careful consideration at a dose not exceeding 0.01 mmol/kg body weight. More than one dose should not be used during a scan. Because of the lack of information on repeated administration, Ambelvist injections should not be repeated unless the interval between injections is at least 7 days.
The safety of gadoquatrane has not been established in preterm neonates.
4.2.3.2 Elderly (aged 65 years and above)
No dose adjustment is required (see section 5.2 Pharmacokinetic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Caution should be exercised in elderly patients (see section 4.4 Special warnings and precautions for use – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
4.2.3.3 Patients with renal impairment
No dose adjustment is required (see section 5.2 Pharmacokinetic properties, Patients with renal impairment – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Ambelvist should only be used in patients with severe renal impairment (GFR< 30 mL/min/1.73 m2) and in patients in the perioperative liver transplantation period after careful benefit/risk assessment and if the diagnostic information is essential and not available with non-contrast enhanced MRI (see section 4.4 Special warnings and precautions for use – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). If it is necessary to use Ambelvist, the dose should not exceed 0.01 mmol/kg body weight. More than one dose should not be used during a scan. Because of the lack of information on repeated administration, Ambelvist injections should not be repeated unless the interval between injections is at least 7 days.
Contraindications
4.3 CONTRAINDICATIONS
Hypersensitivity to any of the ingredients.
